We've compiled it recently 12 Best Growth Stocks to Buy and Hold for Long-Term. In this article, we will explore the position of Argenx SE (NASDAQ:ARGX) against other growth stocks.
The market closed last week was mostly lower, but the S&P 500 has risen more than 7% since April 11, indicating a return positive sentiment. On May 10, David Lefkowitz, an equity strategist at UBS Global Wealth Management, joined CNBC to discuss his bull case for U.S. stocks. Lefkowitz acknowledged the volatility that has been around since the tariff announcement; however, he believes the background remains rather constructive. He elaborated on the market having some important buy signals since early April, characterized by the volatility index giving the highest reading, investors are cautious in their emotions and their position is frustrated. Historically, whenever these things happened in the past, U.S. stocks performed well in the first 6 to 12 months. Lefkowitz noted that he was less concerned about daily news and volatility, as markets would become volatile in terms of trade negotiations. Instead, he is more focused on bigger situations, which suggests that the stock will eventually be higher in the next 12 months.
In answering questions about the recent market rebound, Lefkowitz stressed that when the volatility index declines, as has been the past few weeks, history tells us that the market is not the new low. Although the market will still be a bit cut. However, it is expected to remain within the historical average of 5%. In addition, stock strategists don’t care about valuations and believe that once the company starts publishing earnings growth, the background will help the market reach the next high price.
Lefkowitz noted that he likes worldly growth stocks when talking about his most convicted department. He elaborated on the growth of as an industry earlier this year, due to doubts about AI trends and its ability to generate ROI. This has caused the industry to be at the bottom of the market. However, Lefkowitz believes that demand for AI products and complex infrastructure will continue to grow in the next few years, resulting in sustainable revenue growth.
To compile a list of 12 best growth stocks for long-term purchases and holdings, we used the Finviz Stock Filter, seeking the Q4 2024 2024 HEDGE FUND database from Alpha and Insider Monkey. Using filters, we summarize a list of growth stocks that have increased their sales by at least 30% over the past 5 years. Next, we searched for 5-year sales growth through cross-checking of Alpha's sales volume and ranked stocks in the order of rising numbers of hedge fund investors.
Why are we interested in stocks that hedge funds to accumulate? The reason is simple: Our research shows that we can beat the market by mimicking the top stocks of the best hedge funds. Our strategy for quarterly newsletters selects 14 small and large stocks every quarter, returning 373.4% since May 2014, beating its benchmark by 218 percentage points (See more details here).
Researchers in a laboratory set full of scientific equipment and lab coats are working together to develop new therapies for autoimmune diseases.
5 years of sales growth: 105.96%
Number of hedge fund holders: 47
Argenx SE (NASDAQ:ARGX) is a commercial-stage biotech company dedicated to developing antibody therapies for autoimmune diseases and cancer. It uses its proprietary discovery platform to leverage the unique features of Llama's immune system and engineer antibody drugs. Its main products, Vyvgart and Vyvgart Hytrulo, have been approved in the United States, Europe and Japan.
On May 9, Douglas Tsao, an analyst at HC Wainwright, reiterated his buy rating for the stock, with a target price of $720. Analysts noted that the company grew net product sales for Vyvgart, which exceeded market expectations. The company reported its first quarter results for fiscal 20025 on May 8. Management noted that its total operating revenue was $807 million, driven primarily by net sales of $790 million, up 99% from the same quarter of the previous year. Argenx SE (NASDAQ:ARGX) product sales are geographically diversified, with most sales coming from the United States.
Analyst TSAO noted that the upcoming Vyvgart pre-installed syringes (PFS) are expected to improve patient access and convenience. The company's management also hopes that self-injection will further expand patient access by more ease of self-management and gaining new patient populations. Argenx SE (NASDAQ:ARGX) is one of the best growth stocks to buy and hold for a long time.
Artisan Small Cap Fund pointed out the following about Argenx SE (NASDAQ:ARGX) in its 4Q 2024 investor letter:
“We ended our investment campaigns in argenx SE (NASDAQ:ARGX), Tyler Technologies and Interparfums. Shares of Argenx have continued their year-to-date ascent due to multiple positive developments, including FDA approval to promote VYVGART® for chronic inflammation demyelinating polyradiculoloneuropathy (CIDP) and strong sales execution of VYVGART®'s first approved indication in the muscle weakness.
Overall argx Ranked 9 On our list of the best growth inventory we buy and hold for a long time. Although we acknowledge that Argx's potential is an investment, our belief is that AI stocks have higher returns in a shorter time frame and do this in a shorter time frame. AI stocks have risen since the beginning of 2025, while popular AI stocks have lost about 25%. If you are looking for AI stocks that are more promising than ARGX but have less than 5 times its earnings, check out our report Cheapest AI stocks.
Read the next article: Buy 20 Best AI Stocks Now According to the billionaire, there are now 30 best stocks to buy.
Disclosure: None. This article was originally published in Insider Monkey.